Al's Comment:

 The results look promising but it is hard to judge what the natural progression of these tumors would be without the drug. People with nonenhancing tumors with IDH mutations do much better than enhancing tumors with or without the mutation. More research needs to be done, and they probably should have tried to set up a virtual control group - select patients from a database with the same entry criteria who did not receive the drug so we have a frame of references.

 


Posted on: 06/29/2021

Safety and Efficacy of Vorasidenib in Recurrent or Progressive Glioma

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!